Michael Benkowitz, an insider at United Therapeutics Corp (UTHR), purchased 14,625 shares of the company's stock on December 14, 2025, at a price of $117.76 per share, totaling approximately $1.72 million. Following this transaction, Benkowitz holds a total of 14,625 shares in United Therapeutics.
This insider buying activity may indicate confidence in the company's future prospects, as executives typically have access to non-public information regarding their firm's operations. However, it is essential for investors to consider that insider transactions can be influenced by various personal or regulatory factors.
The transparency provided by such transactions is crucial, as they must be reported to the SEC. While this buying activity from a single insider is one data point, it should be evaluated alongside broader trends in insider behavior and other fundamental and technical indicators.
United Therapeutics, a biotechnology company headquartered in Silver Spring, Maryland, focuses on developing and commercializing therapies for patients with chronic and life-threatening conditions. The firm markets treatments for pulmonary arterial hypertension and has a market capitalization of $20.5 billion. Upcoming earnings are anticipated on July 28, 2026, with an estimated EPS of $7.57 and revenue of $864.0 million.